[非小细胞肺癌化疗和免疫检查点抑制剂致急性肾损伤1例报告]。

Zhonghua nei ke za zhi Pub Date : 2023-05-01 DOI:10.3760/cma.j.cn112138-20220520-00392

X F Zheng, Y C Dong, Q Bian

{"title":"[非小细胞肺癌化疗和免疫检查点抑制剂致急性肾损伤1例报告]。","authors":"X F Zheng, Y C Dong, Q Bian","doi":"10.3760/cma.j.cn112138-20220520-00392","DOIUrl":null,"url":null,"abstract":"患者男性，67岁。因肺腺癌行卡铂-培美曲塞方案化疗，联合免疫检查点抑制剂（ICIs）治疗肿瘤2个疗程后血肌酐252 μmol/L，肾组织活检病理提示急性肾小管坏死合并局灶性急性间质性肾炎，肾间质和肾小管淋巴细胞CD4浸润强阳性，程序性死亡受体1（PD-1）阳性，考虑为化疗药联合ICIs相关肾损伤。停用化疗及免疫治疗，予患者口服甲泼尼龙20 mg/d治疗4周后，规律减量至第9周停药，复查血肌酐98 μmol/L。恢复卡铂-培美曲塞联合化疗，后续培美曲塞单药化疗维持。肾组织活检是明确诊断及指导后续治疗的重要手段。.","PeriodicalId":24000,"journal":{"name":"Zhonghua nei ke za zhi","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Acute kidney injury caused by chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer: a case report].\",\"authors\":\"X F Zheng, Y C Dong, Q Bian\",\"doi\":\"10.3760/cma.j.cn112138-20220520-00392\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"患者男性，67岁。因肺腺癌行卡铂-培美曲塞方案化疗，联合免疫检查点抑制剂（ICIs）治疗肿瘤2个疗程后血肌酐252 μmol/L，肾组织活检病理提示急性肾小管坏死合并局灶性急性间质性肾炎，肾间质和肾小管淋巴细胞CD4浸润强阳性，程序性死亡受体1（PD-1）阳性，考虑为化疗药联合ICIs相关肾损伤。停用化疗及免疫治疗，予患者口服甲泼尼龙20 mg/d治疗4周后，规律减量至第9周停药，复查血肌酐98 μmol/L。恢复卡铂-培美曲塞联合化疗，后续培美曲塞单药化疗维持。肾组织活检是明确诊断及指导后续治疗的重要手段。.\",\"PeriodicalId\":24000,\"journal\":{\"name\":\"Zhonghua nei ke za zhi\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zhonghua nei ke za zhi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn112138-20220520-00392\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhonghua nei ke za zhi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112138-20220520-00392","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Acute kidney injury caused by chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer: a case report].

患者男性，67岁。因肺腺癌行卡铂-培美曲塞方案化疗，联合免疫检查点抑制剂（ICIs）治疗肿瘤2个疗程后血肌酐252 μmol/L，肾组织活检病理提示急性肾小管坏死合并局灶性急性间质性肾炎，肾间质和肾小管淋巴细胞CD4浸润强阳性，程序性死亡受体1（PD-1）阳性，考虑为化疗药联合ICIs相关肾损伤。停用化疗及免疫治疗，予患者口服甲泼尼龙20 mg/d治疗4周后，规律减量至第9周停药，复查血肌酐98 μmol/L。恢复卡铂-培美曲塞联合化疗，后续培美曲塞单药化疗维持。肾组织活检是明确诊断及指导后续治疗的重要手段。.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Zhonghua nei ke za zhi

自引率

0.00%

发文量